Ausgabe 1/2020
Inhalt (15 Artikel)
Looking Back on 2019 in Rheumatology and What to Expect from 2020
Roy Fleischmann
Cardiovascular Comorbidities in Psoriatic Disease
Agnes Szentpetery, Muhammad Haroon, Oliver FitzGerald
Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis
Daniel J. DeMizio, Laura B. Geraldino-Pardilla
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
Roy Fleischmann, Vipul Jairath, Eduardo Mysler, Dave Nicholls, Paul Declerck
Clinical, Economic, and Humanistic Burden Associated With Delayed Diagnosis of Axial Spondyloarthritis: A Systematic Review
Esther Yi, Amit Ahuja, Tanvi Rajput, Aneesh Thomas George, Yujin Park
Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population
Sara L. Gale, Huong Trinh, Nitya Mathew, Angelika Jahreis, Celia J. F. Lin, Khaled Sarsour
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study
Peter H. Schafer, Alan J. Kivitz, Jianglin Ma, Shimon Korish, Donna Sutherland, Li Li, Ada Azaryan, Jolanta Kosek, Mary Adams, Lori Capone, Eun Mi Hur, Douglas R. Hough, Garth E. Ringheim
Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data
Paul Emery, Daniel E. Furst, Petra Kirchner, Simone Melega, Stuart Lacey, Patricia B. Lehane
Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis
Christina A. Spivey, Kevin L. Winthrop, Jenny Griffith, Cameron M. Kaplan, Yanru Qiao, Arnold E. Postlethwaite, Junling Wang
A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis
Hisashi Yamanaka, Naoyuki Kamatani, Yoshiya Tanaka, Toshihiko Hibino, Edit Drescher, Juan Sánchez-Bursón, Manfred Rettenbacher, Girish Bhatia, Snehal Gadve, Chirag Shah, Dhananjay Bakhle
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
Jennie H. Best, Steven C. Vlad, Jinglan Pei
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
Jacqueline M. Tarrant, René Galien, Wanying Li, Lovely Goyal, Yang Pan, Rachael Hawtin, Wangshu Zhang, Annegret Van der Aa, Peter C. Taylor
Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study
Jing Zhang, Weiguo Wan, Liyan Miao, Jian Wu, Jun Dong, Yinghua Shen, Cui Xiong, Chao Li, Yu Xue, Guoying Cao, Peiming Ma
Characteristics and Symptom Severity of Patients Reporting Systemic Lupus Erythematosus in the PatientsLikeMe Online Health Community: A Retrospective Observational Study
Elisabeth Nyman, Timothy Vaughan, Barnabas Desta, Xia Wang, Volkan Barut, Cathy Emmas
Comment on “A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout”
Kevin D. B. van Leeuwen, Arthur M. Bohnen